Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study-Reference-Cited by-同舟云学术

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study

Published:2020-07-25 Issue:4 Volume:9 Page:889-911
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Farooq Asim V.,Degli Esposti Simona,Popat Rakesh,Thulasi Praneetha,Lonial Sagar,Nooka Ajay K.,Jakubowiak Andrzej,Sborov Douglas,Zaugg Brian E.,Badros Ashraf Z.,Jeng Bennie H.,Callander Natalie S.,Opalinska Joanna,Baron January,Piontek Trisha,Byrne Julie,Gupta Ira,Colby Kathryn

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s40123-020-00280-8.pdf

Reference69 articles.

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

2. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187–99.

3. National Cancer Institute. Surveillance, epidemiology, and end results program. cancer stat facts: myeloma; 2020. https://seer.cancer.gov/statfacts/html/mulmy.html.

4. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–9.

5. Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1–7.

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial;Blood Cancer Journal;2024-09-11

2. Ocular side effects of anticancer agents used in the treatment of gynecologic cancers;Gynecologic Oncology;2024-09

3. Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report;Blood Cancer Journal;2024-08-07

4. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies;The Oncologist;2024-07-24

5. Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?;Journal of Ocular Pharmacology and Therapeutics;2024-07-08